Switching to guselkumab in moderate-to-severe psoriasis: Role of patient-reported outcomes and hospital pharmacists

• Autores: Gabriel Antonio Mercadal Orfila, Eugenia Escrivá Sancho, Ignacio Blasco Mascaró, Carla Liñana Granell, Rocío Romero Barco
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 23, Nº. 3, 2021, págs. 180-184
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: The study objective was to assess the value of patient-reported outcomes (PRO) in guiding the switching of biological agents in patients with moderate-to-severe psoriasis attending hospital pharmacy clinics.

    Method: At the suggestion of hospital pharmacists, 45 patients completed the Psoriasis Symptoms and Signs Diary with seven-day recall (PSSD_7D). Those with a PSSD_7D score of ≥20 were referred to the dermatology service for switching to guselkumab. The PSSD_7D score was reassessed after one, six and 12 months of guselkumab therapy.

    Results: Fourteen patients had a PSSD_7D score of ≥20. All were accepted for switching to guselkumab at standard doses. An improvement in the mean PSSD_7D score was already clear within the first month of guselkumab therapy. After 12 months, the score was 83.4% lower than at baseline.

    Conclusions: A PRO instrument could be useful in clinical practice to guide biological therapy in patients with psoriasis